U.S. health agency tells Grassley there is no EpiPen deal yet

From Reuters:

Mylan NV has yet to reach a settlement with the U.S. Department of Justice over the classification in the Medicaid program of its life-saving EpiPen allergy treatment, according to a letter from a regulatory agency disclosed on Thursday.

Mylan said in October that it would pay $465 million to resolve allegations it underpaid U.S. government healthcare programs. The company told Reuters in November it was working to finalize that deal.

However, there is no agreement so far, according to the letter to Senator Charles Grassley from the outgoing head of the Centers for Medicare & Medicaid Services (CMS), Andrew Slavitt. The letter was made public by Grassley.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: